Tyra Biosciences Gets Rare Pediatric Disease Designation For Achondroplasia Therapy
By Ben Glickman
Tyra Biosciences said it received Rare Pediatric Disease Designation from regulators for its potential treatment for a form of dwarfism.
The Carlsbad, Calif.-based biotechnology company said Thursday the U.S. Food and Drug Administration had granted the designation to TYRA-300 as a potential treatment of achondroplasia.
The company said achondroplasia is the most common form of dwarfism and has limited available therapies.
Tyra plans to submit an Investigational New Drug application to the FDA in the second half of 2024, which would allow the company to begin a Phase 2 clinical trial examining dose cohorts.
RPD designation is given by the FDA to potential drugs to treat rare serious or life-threatening diseases which primarily affect children.
Write to Ben Glickman at ben.glickman@wsj.com
(END) Dow Jones Newswires
February 01, 2024 18:05 ET (23:05 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.-
What’s Happening in the Markets This Week
-
Worst-Performing Stock ETFs of the Quarter
-
Q3 in Review and Q4 2024 Market Outlook
-
Top-Performing Stock ETFs of the Quarter
-
September Jobs Report Forecasts Show Moderate Hiring Gains
-
Port Strike a Headache for Shippers but a Potential Tailwind for Certain US Transport Stocks
-
13 Charts on Q3′s Roller-Coaster Rally for Stocks and Bonds
-
5 Stocks to Buy Instead of Overpriced US Equities
-
Consumer Defensives: Despite Angst, Thirsty Investors Have Names to Pursue
-
Industrials: Many Stocks Overvalued After Q3 Outperformance
-
Basic Materials: Despite Index Rise, We See Multiple Long-Term Opportunities
-
What the Election Could Mean for Big Tech Stocks
-
3 Lessons From Recent Stock Market Drama
-
Consumer Cyclicals: Even Amid Moderating Consumer Spending, We See Discounts
-
Healthcare: Valuations Look Fair Overall, With Select Industries Still Undervalued
-
Utilities: Falling Interest Rates, Growth Outlook Boosting Stocks